Search

everythinglearnresearchcommunity

for

Search:↓

Sacituzumab govitecan improves quality of life and extends life for breast cancer patients compared to standard chemotherapy.

Docetaxel is effective against various cancers but mainly causes neutropenia.

Cytarabine can cause multiple organ toxicities, especially neurotoxicity, but better research methods are needed to fully understand and predict these effects.

Combining Ficlatuzumab and Gefitinib can cause severe hair loss.

Cetuximab can cause unusual hair growth and hair loss.

The combination therapy is effective and well-tolerated for treating esophageal cancer.

New cancer drugs can cause skin side effects like rashes, dry skin, hair changes, and nail problems.

Personalized treatment based on detailed tumor analysis successfully managed and reduced the patient's aggressive hair follicle cancer.

Abemaciclib can cause skin, hair, and nail problems, leading some patients to stop using it.

BI 2536 had limited effectiveness against several advanced cancers and caused significant side effects.

Docetaxel often causes hair loss, with limited effective treatments and no cure for permanent hair loss.

Penguin Cold Caps help most patients keep at least half their hair during chemotherapy.

Cinobufacin with chemotherapy improves treatment response and quality of life in advanced breast cancer patients while reducing some side effects.

Eribulin-based chemotherapy is more effective and has fewer side effects for advanced triple-negative breast cancer.

CDK4/6 inhibitors can protect hair cells from chemotherapy damage.

Combining DEB-BACE with chemotherapy is more effective and has fewer side effects than chemotherapy alone for treating unresectable lung squamous cell carcinoma.

The new chemotherapy combination of WP 631 and Epothilone B shows enhanced effectiveness against ovarian cancer but requires more research on its safety.

Pemetrexed with cisplatin is safer and more effective than gemcitabine with cisplatin for advanced lung cancer.

Kanglaite injection with chemotherapy improves treatment and reduces side effects for advanced lung cancer.

Etoposide makes radiation therapy more effective against tumors without major side effects.

Topical calcitriol may reduce hair loss from chemotherapy at higher doses.

More research is needed to understand chemotherapy-induced hair loss and its phases.

Tebentafusp-tebn improves survival rates in uveal melanoma patients but has common side effects like rash and fatigue.

Patients with metastatic breast cancer treated with epirubicin and docetaxel had a good response and maintained their quality of life.

Topical calcitriol appears safe and may reduce hair loss during chemotherapy.

Docetaxel and oxaliplatin are effective and have manageable side effects for recurrent platinum-sensitive ovarian cancer.

Effective management of side effects is crucial for safe use of sacituzumab govitecan in advanced breast cancer treatment.

The drug IPI-926 is safe at 160 mg daily and may help treat certain tumors, especially basal cell carcinoma.

Combining ficlatuzumab and gefitinib can cause severe scarring hair loss.